Lund, Sweden — 10 June 2022 — Camurus (NASDAQ STO: CAMX) invites investors, analysts and media to a Capital Markets and R&D Day on 6 September 2022 in Stockholm, Sweden.
During the event, members of Camurus’ senior management will provide an update on the company strategy, business progress and key R&D pipeline programs. Further insights will be provided by leading clinical experts within Camurus’ therapeutic focus areas.
Time: Tuesday 6 September 2022, 1 pm – 5 pm CET
Venue: IVA Conference Center, Grev Turegatan 16, Stockholm
Registration for analysts, investors, and journalists
To participate, please register no later than 30 August at CMD@camurus.com.
A detailed program will be provided at Camurus website www.camurus.com two weeks ahead of the event.
For more information
Fredrik Tiberg, President & CEO, Head R&D
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
This information was submitted for publication at 8:00 am CET on 10 June 2022.